GlassScriptPhysician profile
Aarisha Shrestha
NPI 1518493956
$1,654.37
in general payments reported to CMS, 2019-2025
16 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $88.37 · 2022: $113 · 2023: $235 · 2024: $115 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.69 | 2023-2025 | Wegovy, Ozempic |
| Insmed, INC. | $231.89 | 2019 | |
| Boston Scientific Corporation | $119.89 | 2019 | |
| Biocryst US Sales Co., LLC | $115.00 | 2024 | Orladeyo |
| Xeris Pharmaceuticals, INC. | $115.00 | 2025 | Recorlev |
| Mallinckrodt Hospital Products INC. | $115.00 | 2023 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $112.71 | 2022 | |
| Merck Sharp & Dohme LLC | $111.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $103.74 | 2019 | |
| Abbvie INC. | $90.13 | 2025 | |
| Janssen Pharmaceuticals, INC | $88.37 | 2020 | |
| Allergan, INC. | $78.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.60 | 2025 | Breztri, Airsupra |
| Biogen, INC. | $26.94 | 2025 | Spinraza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.41 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarisha Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.